完全に切除されたメルケル細胞癌 (ADMEC- O) の治療に対するニボルマブによる補助免疫療法: ランダム化され,オープンラベルで実施された第2相試験による無疾患生存結果
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。副薬ニボルマブは切除されたメルケル細胞癌 (MCC) の無疾患生存率を向上させた. この免疫チェックポイント阻害剤は,手術後のMCC再発を予防する有望な効果を示していますが,全生存データはまだ未発表です.
科学分野
- 腫瘍学
- 免疫療法
- 皮膚科
背景
- メルケル細胞癌 (MCC) は,治療後でも高い再発率を持つ攻撃的な皮膚癌です.
- PD- 1/ PD- L1を標的とした免疫チェックポイント阻害剤は,進行したMCCにおいて有効であることが示されています.
- 切除されたMCCでは,効果的な補助的な全身療法が必要である.
研究 の 目的
- 完全に切除されたMCCの患者における補助薬ニボルマブの有効性と安全性を評価する.
- 第2相試験における主要なエンドポイントとして,無疾患生存率 (DFS) を評価する.
- 2つ目のエンドポイントとして,全生存率と安全性を調べる.
主な方法
- 完全に切除されたMCCにおける観察とニボルマブを比較した多センターランダム化フェーズ2試験.
- 患者はニボルマブ (480 mg 4週間に1回) または観察投与を受けた.
- 12ヶ月と24ヶ月でのDFSは主要エンドポイントで,全体生存率と安全性は二次エンドポイントでした.
主要な成果
- 追跡期間の中央値24. 3ヶ月で,ニボルマブは観察期間と比較してDFS率の改善を示した (12ヶ月で85%,24ヶ月で84%).
- ニボルマブは9% (1年DFS) と10% (2年DFS) の絶対リスク低下を示した.
- 3~4級の有害事象は,観察 (11%),治療に関連した死亡ではなく,ニボルマブ群 (42%) で高かった.
結論
- 補助的なニボルマブは臨床的に実行可能であり,完全に切除されたMCCの再発を予防する潜在的利点を示しています.
- 全体的な生存効果を確認するには,さらなる調査と長期のフォローアップが必要である.
- これらの結果は,MCCに対する補助免疫療法を評価する進行中のランダム化試験を裏付けています.
関連する概念動画
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...